Physician profile
James Q Atkinson, III
NPI 1881671444
$2,131.45
in general payments reported to CMS, 2019-2025
26 companies · $95.44 in 2025
The $95.44 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $69.65 · 2021: $208 · 2022: $204 · 2023: $602 · 2024: $583 · 2025: $95.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $360.06 | 2019-2024 | Airsupra, Breztri |
| Abbvie INC. | $311.77 | 2021-2025 | Dalvance, Teflaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.19 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $161.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $104.19 | 2019-2024 | |
| Almatica Pharma LLC | $71.05 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.70 | 2019 | |
| Glaxosmithkline, LLC. | $50.70 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $33.06 | 2021-2024 | Capvaxive |
| Hikma Pharmaceuticals USA | $28.13 | 2023 | Ryaltris |
| Amarin Pharma, INC. | $26.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.77 | 2024 | |
| Exact Sciences Corporation | $19.90 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $17.11 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2021 | |
| Bausch Health US, LLC | $14.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.83 | 2020 | |
| Valinor Pharma, LLC | $14.20 | 2023 | Movantik |
| Acorda Therapeutics, INC | $13.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.63 | 2019 | |
| Promius Pharma LLC | $13.49 | 2019 | |
| Abbott Laboratories | $13.37 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.00 | 2020 | |
| Ucb, INC. | $12.16 | 2022 | |
| Althera Pharmaceuticals LLC | $10.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.